Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week

finance.yahoo.com/news/why-lillys-bid-verve-therapeutics-170730672.html

In This Article:
Key Points
-
Lilly is acquiring an exciting new program with the agreement to buy Verve Therapeutics.
-
The terms of the deal mean there is still upside for investors, provided Lilly can take VERVE-102 to a phase 3 trial.
Shares in Verve Therapeutics (NASDAQ: VERV)…

This story appeared on finance.yahoo.com, 2025-06-20 17:07:30.
The Entire Business World on a Single Page. Free to Use →